TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02592928

Intervention type: OTHER
Intervention: Inclusion of Spirometry into the Electronic Health Records
Description: Inclusion of the Forced Spirometry into the Electronic Health Records

Intervention type: OTHER
Intervention: Inclusion of Spirometry into the Electronic Health Records
Description: Inclusion of the Forced Spirometry into the Electronic Health Records

Intervention type: OTHER
Intervention: Inclusion of Spirometry into the Electronic Health Records
Description: Inclusion of the Forced Spirometry into the Electronic Health Records
Study: NCT03936309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scar Deactivation Surface Release Technique protocol
Description: ▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
Study: NCT01856192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03936309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scar Infiltration with 0.25-1% Lidocaine
Description: ▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: ▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
Study: NCT00027066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Warfarin
Description: 2mg scored tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin placebo
Description: 325mg aspirin placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin placebo
Description: 2mg scored placebo tablet
Study: NCT02488070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Part of PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)
Description: Intravenously-administered (IV) radioisotope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Part of PET/MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Part of PET/CT and/or PET/MRI scans
Study: NCT01856192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study: NCT02590549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Crosslinking
Description: Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.~After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ufalink
Description: UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
Study: NCT03482453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.
Study: NCT01856192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02287935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limberg flap
Description: Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Karydakis procedure
Description: Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
Study: NCT00934466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2637
Description: Single dose of 120 mg MK2637 capsules in one of five treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK2637
Description: Single dose of 50 mg MK2637 capsules in one of five treatment periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose of placebo only in one of five treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Dextromethorphan
Description: Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Dextromethorphan
Description: Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
Study: NCT03776981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Activation
Description: Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization
Description: Six-week core stabilization program for the group of participants with knee osteoarthritis.
Study: NCT03569280

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enzalutamide or Abiraterone or Apalutamid
Description: Antitumor treatment
Study: NCT01909310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: head extension
Description: the lungs are ventilated with the patient´s head extended

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: head extension
Description: the lungs are ventilated with the patient´s head extended

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neutral position
Description: the lungs are ventilated with the patient´s head in neutral position

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: neutral position
Description: the lungs are ventilated with the patient´s head in neutral position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anaesthesiologist´s position
Description: the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: anaesthesiologist´s position
Description: the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
Study: NCT03482453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-788 placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-788 placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-788 placebo-matching capsules.
Study: NCT04089332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla MRI
Description: A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
Study: NCT00827827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise- Stretching Control
Description: 3x per week upper and lower body stretching mixed with active and passive range of motion exercises
Study: NCT03562299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPure™ XT
Description: A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
Study: NCT03619161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bubbles
Description: All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleach and Bubbles
Description: All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
Study: NCT00261729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: paroxetine 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Prazosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study: NCT01692171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin, Low-Molecular-Weight
Description: single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study: NCT02591784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
Study: NCT03437759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: exosomes derived from mesenchymal stem cells (MSC-Exo)
Description: After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
Study: NCT03421652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
Study: NCT04572620

Intervention type: DRUG
Intervention: Rituximab
Description: 375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.

Intervention type: DRUG
Intervention: Abatacept
Description: 10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
Study: NCT02526264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program
Description: Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
Study: NCT01761526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
Study: NCT03482453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-788 placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-788 placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 DiC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 DiC.
Study: NCT00054353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo reduced-intensity allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo reduced-intensity allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo reduced-intensity allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo reduced-intensity allogeneic PBSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04089332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Catheter
Description: A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
Study: NCT03843229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini injection
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transarterial Chemoembolization(TACE)
Description: TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization(TACE)
Description: TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinobufacini tablet
Description: The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
Study: NCT04822220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Self-management Programme
Description: Fatigue Self-management Programme
Study: NCT04959370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal fixation implantation of dynamic hip screw
Description: Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation implantation of cannulated compression screw
Description: Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
Study: NCT04228042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT03346876

Intervention type: PROCEDURE
Intervention: Nuss surgery
Description: surgical correction for pectus excacatum
Study: NCT03819153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Study: NCT04313881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match magrolimab administered intravenously
Study: NCT00005076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT00736372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-12
Description: Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
Study: NCT00727272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: One 324 mg capsule administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulphate Tablets 300 mg
Description: One 300 mg tablet administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
Study: NCT02243553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study: NCT04089332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: A battery of cognitive tests will be completed by the subject.